Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion,” was published in the Journal of Vascular and Interventional Radiology (JVIR) and provides a comprehensive overview of percutaneous hepatic perfusion (PHP) with melphalan using Delcath’s HEPZATO KIT™. The article highlights PHP’s rationale, technique, patient selection, clinical outcomes, and future research directions, emphasizing its role as an FDA-approved liver-directed therapy for unresectable hepatic metastases from uveal melanoma (UM) with limited extrahepatic disease.
“The publication of this expert narrative review in JVIR features the growing clinical evidence and consensus supporting the use of PHP as a key treatment option for patients with liver-dominant metastatic uveal melanoma,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “By consolidating insights from leading specialists, this review reinforces the value of HEPZATO KIT in achieving meaningful tumor responses and survival benefits while preserving quality of life. We are encouraged by the highlighted potential for broader applications and combinations with systemic therapies, which align with our ongoing efforts to advance interventional oncology.”
The narrative review synthesizes data from prospective and retrospective studies from leading centers in the US and Europe, collectively demonstrating objective response rates of 36%-72%, median overall survival of 15-20 months, and disease control rates up to 89%. Key highlights include:
- PHP’s suitability for multifocal, bilobar UM liver metastases, delivering high-dose chemotherapy with extracorporeal filtration to minimize systemic toxicity
- Short-stay hospital admissions with discharge within 24 hours
- Advantages over other liver-directed therapies, such as reduced risk of hepatic fibrosis compared to radioembolization in whole-liver treatments
- Quality of life data showing no long-term decline, with scores returning to baseline by Day 28 post-procedure
- Ongoing research into immunotherapy combinations and expansion to other metastatic cancers like breast and colorectal
